A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 105, Issue 2, 2007, Pages 508-516

  McMeekin, D Scott ^a   Sill, Michael W ^b   Benbrook, Doris ^c   Darcy, Kathleen M ^b   Stearns Kurosawa, Deborah J ^d   Eaton, Lynne ^e   Yamada, S Diane ^f  

^a OB/GYN   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^d OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

Author keywords

GOG; Refractory endometrial cancer angiogenesis biomarkers; Thalidomide

Indexed keywords

ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; ENDOTHELIAL PROTEIN C RECEPTOR; THALIDOMIDE; VASCULOTROPIN;

ADULT; AGED; ANEMIA; ANGIOGENESIS; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; CANCER RESISTANCE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSCIOUSNESS; CORRELATION ANALYSIS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; FEMALE; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; LIVER DISEASE; LUNG DISEASE; LYMPHATIC SYSTEM DISEASE; METABOLIC DISORDER; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN SECRETION; SENSORY NEUROPATHY; SIDE EFFECT; SKIN DISEASE; UROGENITAL TRACT DISEASE;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIGENS, CD; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CELL SURFACE; THALIDOMIDE; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34247128217     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.01.019     Document Type: Article

References (45)

1. Jemal A., Seigel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics, 2006. CA Cancer J. Clin. 56 2 (2006) 106-130
2. Thigpen J.T., Brady M.F., Homesley H.D., et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 22 19 (2004) 3902-3908
3. Fleming G.F., Filiaci V.L., Bentley R.C., et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24 h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann. Oncol. 15 (2004) 1173-1178
4. Fleming G.F., Brunetto V.L., Cella D., et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 22 (2004) 2159-2166
5. Randall M., Brunetto G., Muss H., et al. Whole abdominal radiotherapy versus combination doxorubicin-cisplatin chemotherapy in advanced endometrial carcinoma: a randomized phase III trial of the Gynecologic Oncology Group. J. Clin. Oncol. 24 1 (2006) 36-44
6. Salvesen H.B., Iversen O.E., and Akslen L.A. Independent prognostic importance of microvessel density in endometrial cancer. Br. J. Cancer 77 (1998) 1140-1144
7. Mazurek A., Telego M., Pierzynski P., et al. Angiogenesis in endometrial cancer. Neoplasma 45 (1998) 360-364
8. Lee C.N., Cheng W.F., Chen C.A., Chu J.S., Hsieh C.Y., and Hsieh F.J. Angiogenesis of endometrial carcinomas assessed by measurement of intratumoral blood flow, microvessel density, and vascular endothelial growth factor levels. Obstet. Gynecol. 96 (2000) 615-621
9. D'Amato R., Loughnan M., Flynn E., and Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 4082-4085
10. Kerbel R., and Folkman J. Clinical translation of angiogenesis inhibitors. Nat. Rev., Cancer 2 (2002) 727-739
11. Singhal S., Mehta J., Desikan R., et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 18 21 (1999) 1565-1571
12. Abramson N., Stokes P.K., Luke M., Marks A., and Harris J. Ovarian and papillary serous peritoneal carcinoma: pilot study with thalidomide. J. Clin. Oncol. 20 4 (2002) 1147-1149
13. Bertolini F., Mingrone W., Alietti A., et al. Thalidomide in multiple myeloma myelodysplastic syndromes and histiocytes. Analysis of clinical results and of surrogate angiogenesis markers. Ann. Oncol. 12 (2001) 987-990
14. Teo S.K. Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS 7 (2005) E14-E19
15. Stearns-Kurosawa D.J., Swindle K., D'Angelo A., Della valle P., Fattorini A., Caron N., et al. Plasma levels of endothelial protein C receptor respond to anticoagulant treatment. Blood 99 (2002) 526-530
16. Dahlback B., and Villoutreix B.O. Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1311-1320
17. Therasse P., Arbuck S., Eisenhauer, Wanders J., Kaplan R., et al. New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 92 (2000) 205-216
18. Pinedo H.M., Verheul H.M.W., D'Amato R.J., and Folkman J. Involvement of platelets in tumour angiogenesis?. Lancet 352 (1998) 1775-1777
19. Chen T.T., and Ng T.H. Optimal flexible designs in phase II clinical trials. Stat. Med. 17 20 (1998) 2301-2312
20. Grabstald H., and Golbey R. Clinical experiences with thalidomide in patients with cancer. Clin. Pharmacol. Ther. 40 (1965) 298-302
21. Kenyon B.M., Browne F., and D'Amato R.J. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp. Eye Res. 64 (1997) 971-978
22. Verheul H.M., Pangigrahy D., Yuan J., and D'Amatno R.J. Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumor growth in rabbits. Br. J. Cancer 79 1 (1999) 114-118
23. Kotoh T., Dhar D.K., Masunaga R., et al. Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice. Surgery 125 (1999) 536-544
24. Abulafia O., Triest W.E., Sherer D.M., Hansen C., and Ghezzi F. Angiogenesis in endometrial hyperplasia and stage I endometrial carcinoma. Obstet. Gynecol. 86 (1995) 479-485
25. Chen C., Cheng W.F., Lee C.N., et al. Cytosol vascular endothelial growth factor in endometrial carcinoma: correlation with disease-free survival. Gynecol. Oncol. 80 (2001) 207-212
26. Hirai M., Nakagawara A., Oosaki T., Hayashi Y., Hirono M., and Yoshihara T. Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial cancer. Gynecol. Oncol. 80 (2001) 181-188
27. Fine B.A., Valente P.T., Feinstein G.I., and Dey T. VEGF, flt-1, and KDR/flk-1 as prognostic indicators in endometrial carcinoma. Gynecol. Oncol. 76 (2000) 33-39
28. Yokoyama Y., Sato S., Futagami M., et al. Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma. Gynecol. Oncol. 77 (2000) 413-418
29. Talvensaari-Mattila A., Soini Y., and Santala M. VEGF and its receptors (flt-1 and KDR/flk-1) as prognostic indicators in endometrial carcinoma. Tumour Biol. 26 (2005) 81-87
30. Fujimoto J, Toyoki H, Jahan I, et al. Sex-steroid-dependent angiogenesis in uterine endometrial cancers. Ster. Biochem. Mol. Biol. 2005;93-161-5.
31. Bai X., and Mi R. Expression of basic fibroblastic growth factor and microvessel density in endometrial carcinoma. Zhonghua Fu Chan Ke Za Zhi 35 6 (2000) 348-351
32. Wang H., Chen G., and Zhang B. Expression of vascular endothelial growth factor and its receptors in endometrial carcinoma. Chin. J. Pathol. 31 (2002) 391-395
33. Peng X.P., Li J.D., Li M.D., Ye X.M., and Yan W.C. Clinical significance of vascular endothelial growth factor in sera of patients with gynecological malignant tumors. Aizheng 21 (2002) 181-185
34. Shaarawy M., and El-Sharkawy S.A. Biomarkers of intrinsic angiogenic and anti-angiogenic activity in patients with endometrial hyperplasia and endometrial cancer. Acta Oncol. 40 (2001) 513-518
35. Giatromanolaki A., Sivridis E., Brekken R., et al., Tumour and Angiogenesis Research Group. The angiogenic "vascular endothelial growth factor/flk-1 (KDR) receptor" pathway in patients with endometrial carcinoma: prognostic and therapeutic implications. Cancer 92 10 (2001) 2569-2577
36. Eisen T., Boshoff C., Mak I., Sapunar F., Vaughan M.M., Pyle L., et al. Continuous low dose thalidomide: a phase II study of advanced melanoma, renal cell, ovarian, and breast cancer. Br. J. Cancer 82 (2000) 812-817
37. Esmon C.T., Gu J.M., Xu J., Qu D., Stearns-Kurosawa D.J., and Kurosawa S. Regulation and functions of the protein C anticoagulant pathway. Haematologica 84 (1999) 363-368
38. Scheffer G.L., Flens M.J., Hageman S., Izquierdo M.A., Shoemaker R.H., and Scheper R.J. Expression of the vascular endothelial cell protein C receptor in epithelial tumour cells. Eur. J. Cancer 38 (2002) 1535-1542
39. Tsuneyoshi N., Fukudome K., Horiguchi S., et al. Expression and anticoagulant function of the endothelial cell protein C receptor (EPCR) in cancer cell lines. Thromb. Haemost. 85 (2001) 356-361
40. Kurosawa S., Stearns-Kurosawa D.J., Carson C.W., et al. Plasma levels of endothelial cell protein C receptor are elevated in patients with sepsis and systemic lupus erythematosus: lack of correlation with thrombomodulin suggests involvement of different pathological processes. Blood 91 (1998) 725-727
41. Stearns-Kurosawa D.J., Swindle K., D'Angelo A., et al. Plasma levels of endothelial protein C receptor respond to anticoagulant treatment. Blood 99 (2002) 526-530
42. Konigsberg W., Kirchhofer D., Riederer M.A., and Nemerson Y. The TF:VIIa complex: clinical significance, structure-function relationships and its role in signaling and metastasis. Thromb. Haemost. 86 (2001) 757-771
43. Lincoln S., Blessing J., Lee R., and Rocereto T. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 88 (2003) 277-281
44. Thigpen J.T., Buchsbaum H.J., Mangan C., and Blessing J.A. Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Cancer Treat. Rep. 63 (1979) 21-27
45. Kaban L.B., Mulliken J.B., Ezekowitz R.A., Ebb D., Smith P.S., and Folkman J. Anti-angiogenic therapy of a recurrent giant cell tumour of the mandible with interferon alfa-2α. Pediatrics 103 (1999) 1145-1149